 ALPHARETTA, Ga., May 03, 2021 GLOBE NEWSWIRE -- Clearside Biomedical, Inc. Nasdaq: CLSD, a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today the resubmission of its New Drug Application NDA to the U.S. Food and Drug Administration FDA for XIPERETM triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis. 